| Schedule of Selected Financial Information with Respect to Single Operating Segment |
The following table presents selected financial information with respect to the Company's single operating segment for the three and six months ended June 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
Commercial and development revenue |
|
$ |
1,147 |
|
|
$ |
— |
|
|
$ |
2,216 |
|
|
$ |
— |
|
License and collaboration revenue |
|
|
10 |
|
|
|
— |
|
|
|
24 |
|
|
|
52 |
|
Total revenues |
|
|
1,157 |
|
|
|
— |
|
|
|
2,240 |
|
|
|
52 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
3,925 |
|
|
|
— |
|
|
|
6,887 |
|
|
|
— |
|
Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
Clinical and manufacturing |
|
|
50,947 |
|
|
|
26,371 |
|
|
|
90,073 |
|
|
|
49,436 |
|
Other research and development(1) |
|
|
3,710 |
|
|
|
4,960 |
|
|
|
8,314 |
|
|
|
9,363 |
|
Total research and development |
|
|
54,657 |
|
|
|
31,331 |
|
|
|
98,387 |
|
|
|
58,799 |
|
General and administrative |
|
|
28,976 |
|
|
|
17,410 |
|
|
|
49,756 |
|
|
|
32,198 |
|
Total costs and operating expenses |
|
|
87,558 |
|
|
|
48,741 |
|
|
|
155,030 |
|
|
|
90,997 |
|
Loss from operations |
|
|
(86,401 |
) |
|
|
(48,741 |
) |
|
|
(152,790 |
) |
|
|
(90,945 |
) |
Other income, net |
|
|
7,345 |
|
|
|
7,315 |
|
|
|
13,532 |
|
|
|
15,067 |
|
Net loss |
|
$ |
(79,056 |
) |
|
$ |
(41,426 |
) |
|
$ |
(139,258 |
) |
|
$ |
(75,878 |
) |
(1) Other research and development consists of indirect costs incurred for the benefit of the research and development efforts, including certain personnel, supply chain, quality assurance, and regulatory affairs. |
|
|